Subtotal: $185.00
Welcome to WellRxCare. We provides Health medical accessories
Original price was: $950.00.$827.00Current price is: $827.00.
Lytgobi (futibatinib) is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
In Stock
| 35 tablets x 4 mg (7-day supply for 20 mg/day) |
Lytgobi (futibatinib) is a kinase inhibitor indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
Lytgobi is taken as a tablet by mouth once a day, with or without food.
On September 30, 2022, the Food and Drug Administration in the USA has granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
Error: No feed found.
Please go to the Instagram Feed settings page to create a feed.
Reviews
There are no reviews yet.